Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine
- PMID: 29046364
- PMCID: PMC5711508
- DOI: 10.1212/WNL.0000000000004642
Randomized study of IV prochlorperazine plus diphenhydramine vs IV hydromorphone for migraine
Abstract
Objective: To determine outcomes among patients with migraine in the emergency department (ED) who receive IV hydromorphone vs IV prochlorperazine + diphenhydramine.
Methods: This study was conducted in 2 EDs in New York City. Patients who met international criteria for migraine were eligible for participation if they had not used an opioid within the previous month. Clinicians, participants, investigators, and research personnel were blinded to treatment. Patients were randomized in blocks of 4. Participants received hydromorphone 1 mg or prochlorperazine 10 mg + diphenhydramine 25 mg. Diphenhydramine was administered to prevent akathisia, a common side effect of IV prochlorperazine. The primary outcome was sustained headache relief, defined as achieving a headache level of mild or none within 2 hours of medication administration and maintaining that level for 48 hours without the requirement of rescue medication. A planned interim analysis was conducted once 48-hour data were available for 120 patients.
Results: The trial was halted by the data monitoring committee after 127 patients had been enrolled. The primary outcome was achieved in the prochlorperazine arm by 37 of 62 (60%) participants and in the hydromorphone arm by 20 of 64 (31%) participants (difference 28%, 95% confidence interval 12-45, number needed to treat 4, 95% confidence interval 2-9).
Conclusions: IV hydromorphone is substantially less effective than IV prochlorperazine for the treatment of acute migraine in the ED and should not be used as first-line therapy.
Clinicaltrialsgov identifier: NCT02389829.
Classification of evidence: This study provides Class I evidence that for patients in the ED with migraine, IV prochlorperazine + diphenhydramine is superior to IV hydromorphone.
© 2017 American Academy of Neurology.
Figures
Comment in
-
IV prochlorperazine + diphenhydramine improved migraine pain relief more than IV hydromorphone in the ED.Ann Intern Med. 2018 Mar 20;168(6):JC28. doi: 10.7326/ACPJC-2018-168-6-028. Ann Intern Med. 2018. PMID: 29554666 No abstract available.
Similar articles
-
A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine-associated symptoms: A post hoc analysis.Headache. 2021 Sep;61(8):1227-1233. doi: 10.1111/head.14185. Epub 2021 Aug 7. Headache. 2021. PMID: 34363617 Clinical Trial.
-
Opioid-Induced "Likeability" and "Feeling Good" Are Not Associated With Return Visits to an ED Among Migraine Patients Administered IV Hydromorphone.Headache. 2018 May;58(5):750-754. doi: 10.1111/head.13292. Epub 2018 Mar 8. Headache. 2018. PMID: 29516486 Clinical Trial.
-
Emergency Department Use of Intravenous Prochlorperazine for Acute Migraine.Adv Emerg Nurs J. 2018 Jul/Sep;40(3):148-154. doi: 10.1097/TME.0000000000000203. Adv Emerg Nurs J. 2018. PMID: 30059368
-
Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications.Headache. 2012 Mar;52(3):467-82. doi: 10.1111/j.1526-4610.2012.02097.x. Headache. 2012. PMID: 22404708 Review.
-
Intravenous Migraine Treatment in Children and Adolescents.Curr Pain Headache Rep. 2020 Jul 8;24(8):45. doi: 10.1007/s11916-020-00867-7. Curr Pain Headache Rep. 2020. PMID: 32638172 Review.
Cited by
-
In vitro synergistic antiviral activity of repurposed drugs against enterovirus 71.Arch Virol. 2024 Jul 30;169(8):169. doi: 10.1007/s00705-024-06097-1. Arch Virol. 2024. PMID: 39078431
-
Breaking the cycle: unraveling the diagnostic, pathophysiological and treatment challenges of refractory migraine.Front Neurol. 2023 Sep 27;14:1263535. doi: 10.3389/fneur.2023.1263535. eCollection 2023. Front Neurol. 2023. PMID: 37830088 Free PMC article. Review.
-
Breakthroughs on the clinical management of headache and questions that need to be solved.Ibrain. 2021 Dec 9;7(4):298-308. doi: 10.1002/ibra.12003. eCollection 2021 Winter. Ibrain. 2021. PMID: 37786564 Free PMC article. Review.
-
Headache in the Emergency Department: A Multicenter Observational Study from Singapore.Medicina (Kaunas). 2023 Jul 21;59(7):1340. doi: 10.3390/medicina59071340. Medicina (Kaunas). 2023. PMID: 37512151 Free PMC article.
-
Acute Headache Management for Patients with Subarachnoid Hemorrhage: An International Survey of Health Care Providers.Neurocrit Care. 2023 Apr;38(2):395-406. doi: 10.1007/s12028-022-01571-7. Epub 2022 Aug 2. Neurocrit Care. 2023. PMID: 35915347
References
-
- Friedman BW, West J, Vinson DR, Minen MT, Restivo A, Gallagher EJ. Current management of migraine in US emergency departments: an analysis of the National Hospital Ambulatory Medical Care Survey. Cephalalgia 2015;35:301–309. - PubMed
-
- Langer-Gould AM, Anderson WE, Armstrong MJ, et al. . The American Academy of Neurology's top five choosing wisely recommendations. Neurology 2013;81:1004–1011. - PubMed
-
- Loder E, Weizenbaum E, Frishberg B, Silberstein S; American Headache Society Choosing Wisely Task Force. Choosing wisely in headache medicine: the American Headache Society's list of five things physicians and patients should question. Headache 2013;53:1651–1659. - PubMed
-
- Orr SL, Friedman BW, Christie S, et al. . Management of adults with acute migraine in the emergency department: the American Headache Society evidence assessment of parenteral pharmacotherapies. Headache 2016;56:911–940. - PubMed
-
- Colman I, Rothney A, Wright SC, Zilkalns B, Rowe BH. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology 2004;62:1695–1700. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous